Prosthesis (i.e. – artificial body members) – parts thereof – or ai – Arterial prosthesis – Stent structure
Reexamination Certificate
2000-10-30
2004-07-06
McDermott, Corrine (Department: 3738)
Prosthesis (i.e., artificial body members), parts thereof, or ai
Arterial prosthesis
Stent structure
C623S001420
Reexamination Certificate
active
06758859
ABSTRACT:
FIELD OF THE INVENTION
This invention relates generally to implantable devices, such as expandable intraluminal prosthesis. More particularly, this invention relates to an implantable prosthesis having a plurality of depots formed in the device to deliver fluid to tissues.
BACKGROUND OF THE INVENTION
A variety of surgical procedures and medical devices are currently used to relieve intraluminal constrictions caused by disease or tissue trauma. An example of one such procedure is percutaneous transluminal coronary angioplasty (PTCA). PTCA is a catheter-based technique whereby a balloon catheter is inserted into a blocked or narrowed coronary lumen of the patient. Once the balloon is positioned at the blocked lumen or target site, the balloon is inflated causing dilation of the lumen. The catheter is then removed from the target site thereby allowing blood to freely flow through the unrestricted lumen.
Although PTCA and related procedures aid in alleviating intraluminal constrictions, such constrictions or blockages reoccur in many cases. The cause of these recurring obstructions, termed restenosis, is due to the body's response to the surgical procedure and implant. As a result, the PTCA procedure may need to be repeated to repair the damaged lumen.
Stents or drug therapies, either alone or in combination with the PTCA procedure, are often used to avoid or mitigate the effects of restenosis at the surgical site. In general, stents are small, cylindrical devices whose structure serves to create or maintain an unobstructed opening within a lumen. The stents are typically made of biocompatible alloys and metals, such as stainless steel and Nitinol™, and are delivered to the target site via a catheter. Although the stents are effective in opening the stenotic lumen, the foreign material and structure of the stents themselves may exacerbate the occurrence of restenosis or thrombosis.
Drugs or similar agents that limit or dissolve plaque and clots are used to reduce, or in some cases eliminate, the incidence of restenosis and thrombosis. The term “drug(s),” as used herein, refers to all therapeutic agents, diagnostic agents/reagents and other similar chemical/biological agents, including combinations thereof, used to treat and/or diagnose restenosis, thrombosis and related conditions. Examples of various drugs or agents commonly used include heparin, hirudin, antithrombogenic agents, steroids, ibuprofen, antimicrobials, antibiotics, tissue plasma activators, monoclonal antibodies, and antifibrosis agents.
Since the drugs are applied systemically to the patient, they are absorbed not only by the tissues at the target site, but by all areas of the body. As such, one drawback associated with the systemic application of drugs is that areas of the body not needing treatment are also affected. To provide more site-specific treatment, stents can be used as a means of delivering the drugs exclusively to the target site. The drugs are stored in a tissue-compatible polymer, such as silicone, polyurethane, polyvinyl alcohol, polyethylene, polyesters, hydrogels, hyaluronate, various copolymers or blended mixtures thereof. The polymer matrix is applied to the surfaces of the stent generally during the manufacture of the stent. By positioning the stent at the target site, the drugs can be applied directly to the area of the lumen requiring therapy or diagnosis.
In addition to the benefit of site-specific treatment, drug-loaded stents also offer longterm treatment and/or diagnostic capabilities. These stents include a biodegradable or absorbable polymer suspension that is saturated with a particular drug. In use, the stent is positioned at the target site and retained at that location either for a predefined period or permanently. The polymer suspension releases the drug into the surrounding tissue at a controlled rate based upon the chemical and/or biological composition of the polymer and drug.
The above-described devices and methods for treatment of restenosis and thrombosis, and other similar conditions not specifically described, offer many advantages to potential users. However, it has been discovered that such devices and methods may be deficient in their current drug-loading and drug-delivery characteristics. In particular, the amount or volume of drug capable of being delivered to the target site may be insufficient due to the limited surface area of the stent.
SUMMARY OF THE INVENTION
In view of the above, it is apparent that there is a need to provide a fluid delivery device offering increased drug loading capabilities for stents and other prosthetic devices. It is also desirable that the drug-delivery device allows fluids to be released at variable and/or independent rates. There is also a need to provide a method of manufacturing such an improved fluid delivery device that is convenient, efficient and cost effective.
In accordance with various aspects of the present invention, an implantable prosthesis, one example of which includes a stent, has a body structure with a hollow bore that extends longitudinally through the body structure. The outer surface of the prosthesis is capable of contacting an inner lumen surface of a passageway. In addition, the body structure of the prosthesis has one or more elements having a width and a thickness. The width of the element(s) is variable from a nominal or conventional width to an increased width.
In another aspect of the present invention, a variable width prosthesis includes one or more depots formed on the elements of the prosthesis. The depots have an open end, a closed end, a diameter and a depth that is less than the thickness of the body structure of the prosthesis. In general, the depots are formed at the increased width sections of the elements. The depots have an increased diameter that improves the drug loading capacity of the prosthesis. The variable width of the prosthesis also gives a wavy appearance to the profile of each element. The wavy appearance of the elements of the prosthesis improves the gripping of the prosthesis onto the delivery system. In addition, the variable width of each element is designed to mesh with the variable width of adjacent elements, thereby optimizing the profile of the prosthesis.
REFERENCES:
patent: 4459252 (1984-07-01), MacGregor
patent: 5059211 (1991-10-01), Stack et al.
patent: 5163952 (1992-11-01), Froix
patent: 5306286 (1994-04-01), Stack et al.
patent: 5514154 (1996-05-01), Lau et al.
patent: 5527337 (1996-06-01), Stack et al.
patent: 5569295 (1996-10-01), Lam
patent: 5603721 (1997-02-01), Lau et al.
patent: 5700286 (1997-12-01), Tartaglia et al.
patent: 5713949 (1998-02-01), Jayaraman
patent: 5766710 (1998-06-01), Turnlund et al.
patent: 5769883 (1998-06-01), Buscemi et al.
patent: 5843172 (1998-12-01), Yan
patent: 5855600 (1999-01-01), Alt
patent: 5873904 (1999-02-01), Ragheb et al.
patent: 5891108 (1999-04-01), Leone et al.
patent: 5972027 (1999-10-01), Johnson
patent: 6071305 (2000-06-01), Brown et al.
patent: 6120536 (2000-09-01), Ding et al.
patent: 6120847 (2000-09-01), Yang et al.
patent: 6129755 (2000-10-01), Mathis et al.
patent: 6171334 (2001-01-01), Cox
patent: 6203569 (2001-03-01), Wijay
patent: 6206915 (2001-03-01), Fagan et al.
patent: 6254632 (2001-07-01), Wu et al.
patent: 6273908 (2001-08-01), Ndondo-Lay
patent: 6273910 (2001-08-01), Limon
patent: 6273913 (2001-08-01), Wright et al.
patent: 6287628 (2001-09-01), Hossainy et al.
patent: 6299604 (2001-10-01), Ragheb et al.
patent: 6334871 (2002-01-01), Dor et al.
patent: 6379381 (2002-04-01), Hossainy et al.
patent: 6395326 (2002-05-01), Castro et al.
patent: 6416543 (2002-07-01), Hilaire et al.
patent: 6506437 (2003-01-01), Harish et al.
patent: 6562065 (2003-05-01), Shanley
patent: 0875218 (1998-11-01), None
patent: 0850651 (2000-08-01), None
patent: 11-299901 (2002-11-01), None
patent: 90/01969 (1990-03-01), None
patent: 98/23228 (1998-06-01), None
patent: 99/16386 (1999-04-01), None
patent: WO 01/00112 (2001-01-01), None
Dang Kenny L.
Ho Henjen
Matin Nazanine
Matthews William H
McDermott Corrine
Squire Sanders & Dempsey L.L.P.
LandOfFree
Increased drug-loading and reduced stress drug delivery device does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Increased drug-loading and reduced stress drug delivery device, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Increased drug-loading and reduced stress drug delivery device will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3200528